These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11103926)

  • 41. Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?
    Cantor WJ; Hellkamp AS; Peterson ED; Zidar JP; Cowper PA; Sketch MH; Tcheng JE; Califf RM; Ohman EM
    J Am Coll Cardiol; 2001 Jun; 37(7):1883-90. PubMed ID: 11401127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis.
    Brophy JM; Belisle P; Joseph L
    Ann Intern Med; 2003 May; 138(10):777-86. PubMed ID: 12755549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.
    Cohen DJ; Breall JA; Ho KK; Weintraub RM; Kuntz RE; Weinstein MC; Baim DS
    J Am Coll Cardiol; 1993 Oct; 22(4):1052-9. PubMed ID: 8409040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An economic approach to clinical trial design and research priority-setting.
    Claxton K; Posnett J
    Health Econ; 1996; 5(6):513-24. PubMed ID: 9003938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease.
    Jaff MR; Cahill KE; Yu AP; Birnbaum HG; Engelhart LM
    Ann Vasc Surg; 2010 Jul; 24(5):577-87. PubMed ID: 20579582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic impact of angioplasty salvage techniques, with an emphasis on coronary stents: a method incorporating costs, revenues, clinical effectiveness and payer mix.
    Vaitkus PT; Witmer WT; Brandenburg RG; Wells SK; Zehnacker JB
    J Am Coll Cardiol; 1997 Oct; 30(4):894-900. PubMed ID: 9316515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
    Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct coronary stenting compared with stenting after predilatation is feasible, safe, and more cost-effective in selected patients: evidence to date indicating similar late outcomes.
    Ijsselmuiden AJ; Tangelder GJ; Cotton JM; Vaijifdar B; Kiemeneij F; Slagboom T; v d Wieken R; Serruys PW; Laarman GJ
    Int J Cardiovasc Intervent; 2003; 5(3):143-50. PubMed ID: 12959731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing the costs and benefits of medical research: the diabetic retinopathy study.
    Drummond MF; Davies LM; Ferris FL
    Soc Sci Med; 1992 May; 34(9):973-81. PubMed ID: 1631610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bayesian models for cost-effectiveness analysis in the presence of structural zero costs.
    Baio G
    Stat Med; 2014 May; 33(11):1900-13. PubMed ID: 24343868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.
    Pietzsch JB; Geisler BP; Garner AM; Zeller T; Jaff MR
    Catheter Cardiovasc Interv; 2014 Oct; 84(4):546-54. PubMed ID: 24782424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economics of coronary stenting and GPIIb/IIIa blockade.
    Weintraub WS
    Eur Heart J; 2001 Aug; 22(16):1366-8. PubMed ID: 11482914
    [No Abstract]   [Full Text] [Related]  

  • 54. Medical economic considerations of coronary stenting.
    Szucs TD
    Schweiz Med Wochenschr; 1999 Nov; 129(45):1701-11. PubMed ID: 10595380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of optimal stenting techniques on cardiac catheterization laboratory resource utilization and costs.
    Sukin CA; Baim DS; Caputo RP; Ho KK; Laham RJ; Flatley MG; Carrozza JP; Cohen DJ
    Am J Cardiol; 1997 Feb; 79(3):275-80. PubMed ID: 9036744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative economic analyses of minimally invasive direct coronary artery bypass surgery.
    Gray DT; Veenstra DL
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):618-24. PubMed ID: 12658204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI).
    Yock CA; Boothroyd DB; Owens DK; Winston C; Hlatky MA
    Am Heart J; 2000 Oct; 140(4):556-64. PubMed ID: 11011328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Financing endoluminal stent prostheses in abdominal aortic aneurysms].
    Lahl W; Bohemann L
    Zentralbl Chir; 1997; 122(9):801-4. PubMed ID: 9454491
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.